Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones

被引:0
|
作者
Zhang, Fan [1 ,2 ,3 ]
Li, Wenjian [1 ,4 ]
机构
[1] Xuzhou Med Univ, Changzhou Clin Coll, Changzhou, Peoples R China
[2] Changzhou Third Peoples Hosp, Dept Endocrinol, Changzhou, Peoples R China
[3] Changzhou Third Peoples Hosp, Dept Clin Nutr, Changzhou, Peoples R China
[4] Changzhou Third Peoples Hosp, Dept Urol, Changzhou, Peoples R China
关键词
Fatty liver index; Metabolic dysfunction-associated steatotic liver disease; Kidney stones; Risk factors; NHANES; BODY-MASS INDEX; NEPHROLITHIASIS; PATHOGENESIS; NAFLD;
D O I
10.1159/000543404
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Introduction: This study aimed to investigate the potential association between the fatty liver index (FLI), metabolic dysfunction-associated steatotic liver disease (MASLD), and the risk of kidney stones using large-scale population-based data. Methods: This study employed a cross-sectional design, utilizing data from the 2007 to 2018 National Health and Nutrition Examination Survey (NHANES) database. A total of 24,342 participants were enrolled in the study, and fatty liver status was assessed by calculating the FLI. MASLD was diagnosed by FLI in conjunction with cardiometabolic criteria. Data on the history of kidney stones were obtained by self-report. We employed logistic regression models to analyze the association between FLI, MASLD, and kidney stone risk and constructed multivariable adjustment models to control for potential confounders. Furthermore, we used restricted cubic spline curve models to investigate the dose-response relationship between FLI and kidney stone risk and conducted subgroup and interaction analyses. Results: The study's results indicate a strong correlation between increasing FLI quartiles and a notable rise in the prevalence of kidney stones. Specifically, the risk of developing kidney stones was 1.68 times higher among participants in the highest FLI quartile compared to those in the lowest. Furthermore, patients with MASLD exhibited a 1.35-fold increased risk of developing kidney stones compared to those with non-MASLD. Subgroup analyses demonstrated that the correlation between MASLD and kidney stone risk was consistent across multiple subgroups. However, a significant interaction was observed in the subgroups of smoking status, physical activity level, and hypertension (interaction p < 0.05). The restricted cubic spline analysis did not yield a statistically significant nonlinear association between FLI and kidney stone risk. However, the study did identify inflection point values for FLI. Conclusion: This study demonstrated an association between FLI and MASLD and the risk of kidney stones. This suggests that these conditions may be pivotal risk factors for kidney stones. Further investigation is required to elucidate these associations' underlying mechanisms and develop efficacious interventions to reduce the risk of kidney stones. Also, formulating personalized prevention and treatment strategies for different population subgroups is paramount.
引用
收藏
页码:115 / 130
页数:16
相关论文
共 50 条
  • [21] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [22] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
    Zheng, Haixiang
    Sechi, Leonardo Antonio
    Navarese, Eliano Pio
    Casu, Gavino
    Vidili, Gianpaolo
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [23] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [24] Metabolic Dysfunction-Associated Steatotic Liver Disease: An Overview of Pharmacotherapy
    El Hussein, Mohamed
    Favell, Daniel
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2025, 21 (02):
  • [25] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [26] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [27] The Association Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Change in Liver Stiffness in Patients With Chronic Hepatitis B
    Patmore, Lesley A.
    van Eekhout, Kirsi
    Koc, oezguer M.
    de Knegt, Robert J.
    Janssen, Harry L. A.
    Brouwer, Willem P.
    Kramer, Matthijs
    Honkoop, Pieter
    de Bruijne, Joep
    Boland, Greet J.
    Postma, Douwe F.
    Blokzijl, Hans
    de Man, Robert A.
    Takkenberg, R. Bart
    Sonneveld, Milan J.
    LIVER INTERNATIONAL, 2025, 45 (03)
  • [28] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [29] Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Jung, Chan-Young
    Koh, Hee Byung
    Park, Keun Hyung
    Joo, Young Su
    Kim, Hyung Woo
    Ahn, Sang Hoon
    Park, Jung Tak
    Kim, Seung Up
    DIABETES & METABOLISM, 2022, 48 (04)
  • [30] Insulin resistance as a mediator in the association between nickel exposure and metabolic dysfunction-associated steatotic liver disease
    Liu, Zhou
    Zhang, Liang
    Wu, Yanrui
    Tan, Zongbiao
    Li, Guang
    Li, Zhenwen
    Zhan, Liying
    Dong, Weiguo
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01)